Targeted alpha therapy of pancreatic tumors in a theranostic setting

The objective of this project is to develop and evaluate therapeutic radiopharmaceuticals for the treatment of pancreatic cancer. Our aim is to create an innovative pipeline of cancer-specific theranostics (therapeutic: ther; diagnostic: anostics) that will improve the treatment options for neuroendocrine tumor patients who are refractory to 177Lu-DOTATATE therapy, or have reached the maximum prescribed cycles of therapy and for pancreatic ductal adenocarcinoma patients with otherwise limited or non-existing treatment alternatives. We will realize this by using three different classes of vector molecules that have completely different modes of binding and we will combine them with potent radioactive payloads such as α-emitters and terbium-161. We hypothesize that this approach will lead to more localized and effective destruction of cancer and cancer-supporting cells compared to standard targeted radiotherapy.

Keywords:Targeted alpha therapy, Positron emission Tomography, Pancreatic cancer, Nuclear medicine, Radiochemistry, Precision Medicine, Theranostics

Disciplines:Radiopharmacy